Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
Frontiers in immunology(2018)
Abstract
[This corrects the article DOI: 10.3389/fimmu.2018.01355.].
MoreTranslated text
Key words
anti-GD2 chimeric antibody,cytokine biomarkers,cytokines,immunotherapy,neuroblastoma,safety
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined